Antiviral treatment is recommended as soon as possible for any patient with suspected or confirmed influenza who:
Decisions about starting antiviral treatment for patients with suspected influenza should not wait for laboratory confirmation of influenza virus infection. Empiric antiviral treatment should be started as soon as possible in the above priority groups. Clinicians can consider early empiric antiviral treatment of non-high-risk outpatients with suspected influenza [e.g., influenza-like illness (fever with either cough or sore throat)] based upon clinical judgement, if treatment can be initiated within 48 hours of illness onset. Antiviral Drug Options
During periods of community co-circulation of influenza viruses and SARS-CoV-2, empiric antiviral treatment of influenza is recommended as soon as possible for the following priority groups: a) hospitalized patients with respiratory illness; b) outpatients with severe, complicated, or progressive respiratory illness; and c) outpatients at higher risk for influenza complications who present with any acute respiratory illness symptoms (with or without fever).
Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza.
Abbreviations: N/A = not applicable, COPD = chronic obstructive pulmonary disease. 1 Oral oseltamivir phosphate is approved by the FDA for treatment of acute uncomplicated influenza within 2 days of illness onset in people 14 days and older, and for chemoprophylaxis in people 1 year and older. Although not part of the FDA-approved indications, use of oral oseltamivir for treatment of influenza in infants less than 14 days old, and for chemoprophylaxis in infants 3 months to 1 year, is recommended by the CDC and the American Academy of Pediatrics. If a child is younger than 3 months old, use of oseltamivir for chemoprophylaxis is not recommended unless the situation is judged critical due to limited data in this age group.
*Note: Oral oseltamivir is the recommended antiviral for patients with severe, complicated, or progressive illness who are not hospitalized, and for hospitalized influenza patients.
Figure: Guide for considering influenza testing and treatment when influenza viruses are circulating in the community (regardless of influenza vaccination history)1 Complete footnotes for this algorithm are available.
Treatment of patients with severe influenza (e.g., those requiring hospitalization) presents multiple challenges. The effect of specific antiviral strategies in serious or life-threatening influenza is not established from clinical trials conducted to support licensure of oral oseltamivir, inhaled zanamivir, intravenous peramivir, or oral baloxavir, as those studies were conducted primarily among previously healthy outpatients with uncomplicated illness. No randomized, placebo-controlled clinical trials have been conducted of monotherapy with neuraminidase inhibitors for treatment of influenza in hospitalized patients. A secondary analysis of a multi-center unblinded clinical trial of oseltamivir treatment started within 24 hours of admission versus standard of care in adults hospitalized for lower respiratory tract infection reported that patients with laboratory-confirmed influenza had a significantly lower risk of clinical failure (composite outcome: failure to improve with 7 days, transfer to ICU care 24 hours after admission, or rehospitalization or death within 30 days) (Wiemken, 2021). Several observational studies in hospitalized influenza patients have shown clinical benefit of neuraminidase inhibitor antiviral treatment compared with no treatment, particularly when started within two days of influenza illness, or as soon as possible after hospital admission, including reducing the duration of hospitalization, and reducing the risk of invasive mechanical ventilation or risk of death (Hiba, 2011; Coffin, 2011; Viasus, 2011; Hsu, 2012; Louie, 2013; Muthuri, 2013; Muthuri, 2014; Miyakawa, 2019; Lytras, 2019; Campbell, 2021; Chen, 2020; Chen, 2020; Venkatesan, 2020; Katzen, 2019; Reacher, 2019). In addition, some observational studies have reported that oral oseltamivir treatment started 4 and 5 days after illness onset in patients hospitalized with suspected or confirmed influenza was associated with lower risk for severe outcomes (EH Lee, 2010; N Lee, 2008; N Lee, 2010; Louie, 2012; McGeer, 2007; Siston, 2010), although one report found this benefit only in hospitalized adult patients in the ICU (Muthuri, 2014). A small number of observational studies and one meta-analysis of observational studies of hospitalized influenza patients reported that neuraminidase inhibitor treatment did not have survival benefit (Choi, 2017; Wolkewitz, 2016; Heneghan, 2016). One randomized clinical trial reported that combination neuraminidase inhibitor (primarily oseltamivir) and baloxavir treatment of hospitalized influenza patients aged ≥12 years did not result in superior clinical benefit (time to clinical improvement) compared to treatment with neuraminidase inhibitor and placebo, indicating that adding baloxavir did not result in additional clinical benefit, but significantly reduced nasopharyngeal influenza viral RNA levels (Kumar, 2022). The following recommendations do not necessarily represent FDA-approved uses of antiviral products but are based on published observational studies and expert opinion and are subject to change as the developmental status of investigational products and the epidemiologic and virologic features of influenza change over time.
Abbreviations: N/A = not approved 1Longer treatment duration may be needed for severely ill patients.
Dose adjustment of oseltamivir is recommended for patients with creatinine clearance between 10 and 60 mL/min and patients with end-stage renal disease (ESRD) undergoing hemodialysis or continuous peritoneal dialysis receiving oseltamivir for the treatment or chemoprophylaxis of influenza. Oseltamivir is not recommended for patients with ESRD not undergoing dialysis. The recommended doses are detailed in Table 3; duration of treatment and chemoprophylaxis is the same as recommended for patients with normal renal function. The dose of intravenous peramivir should be reduced for patients with baseline creatinine clearance below 50 mL/min (see Table 3). No dose adjustment is recommended for inhaled zanamivir for a 5-day course of treatment for patients with renal impairment. Pharmacokinetic analysis did not identify a clinically meaningful effect of renal function on the pharmacokinetics of baloxavir in patients with creatinine clearance 50 mL/min and above. The effects of severe renal impairment on the pharmacokinetics of baloxavir marboxil or its active metabolite, baloxavir, have not been evaluated.
* From package inserts for oseltamivir and peramivir; see FDA Influenza (Flu) Antiviral Drugs and Related Information. Abbreviations: N/A = approved, not recommended
For more information, visit the Seasonal Influenza (Flu) site, email CDC-INFO, or call CDC at 800-CDC-INFO (English and Spanish) or 888-232-6348 (TTY). A more complete list of influenza antiviral references is available. |